Sabril (Vigabatrin) is an antiepileptic drug indicated for the treatment of specific types of epileptic seizures. Given its potential to cause severe and permanent visual impairment, the administration of Sabril must strictly follow medical guidance and be accompanied by close medication monitoring.

What Are the Precautions for Taking Sabril (Vigabatrin)?

Correct Medication Administration and Dosage Form Usage

Both tablets and oral solution can be taken with or without food.

Preparation of oral solution: The provided special oral syringe must be used for accurate measurement and administration.

Dissolve the entire 500 mg powder sachet in 10 mL of cold or room temperature water to achieve a concentration of 50 mg/mL.

Dosage Adjustments for Special Populations

Patients with renal impairment: Sabril is primarily excreted via the kidneys. Adult patients and pediatric patients aged 2 years and above require dosage adjustment based on creatinine clearance.

Elderly patients: They are more prone to renal function decline, and may need dosage adjustment along with renal function monitoring.

Pregnant and lactating women: Based on animal data, Sabril may cause fetal harm. The potential benefits must be carefully weighed against the risks before use during pregnancy. The drug is excreted in breast milk, and its use during lactation is not recommended.

Patients with hepatic impairment: Relevant pharmacokinetic studies are insufficient, so Sabril should be used with caution.

Medication Monitoring for Sabril (Vigabatrin)

Visual Monitoring

Monitoring frequency: Baseline assessment (no later than 4 weeks after initiating treatment), at least once every 3 months during treatment, and approximately 3–6 months after discontinuation.

Monitoring content: It should be performed by an ophthalmology specialist who is proficient in visual field interpretation and capable of conducting dilated indirect ophthalmoscopy.

Special notes: Visual testing in infants is challenging, and visual impairment may not be detected until it becomes severe. For patients who are unable to cooperate with the tests, physicians need to make clinical judgments on whether to continue treatment, and fully communicate the risks with patients or their guardians. Even with frequent monitoring, it may not be possible to prevent all cases of visual impairment. Once visual damage is confirmed, consideration should be given to discontinuing the drug.

Suicidal Risk Monitoring

Like all antiepileptic drugs, Sabril may increase the risk of suicidal thoughts and behaviors.

Patients, their family members and caregivers should be alert to any abnormal changes in mood, behavior or thinking (such as worsening depression, anxiety, insomnia or emergence of suicidal thoughts) and report them to the physician promptly.

Other Laboratory and Imaging Monitoring

Hematological monitoring: There is a risk of anemia, so hemoglobin and hematocrit levels need to be monitored during treatment.

Infant MRI monitoring: Infants with infantile spasms receiving Sabril treatment may exhibit abnormal MRI signals in the brain (e.g., increased T2 signals in the thalamus and basal ganglia), whose clinical significance remains unclear.

Notes on liver function monitoring: Sabril can reduce the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which may interfere with the identification of early liver injury.